journal
MENU ▼
Read by QxMD icon Read
search

Bladder Cancer

journal
https://www.readbyqxmd.com/read/28516160/clinical-trials-corner
#1
Piyush K Agarwal, Cora N Sternberg
No abstract text is available yet for this article.
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516159/challenging-cases-in-urothelial-cancer
#2
Mark S Soloway
No abstract text is available yet for this article.
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516158/a-management-algorithm-for-mitomycin-c-induced-cystitis
#3
Amy N Luckenbaugh, Rory M Marks, David C Miller, Alon Z Weizer, John T Stoffel, Jeffrey S Montgomery
Background/Objective: A post-bladder tumor resection dose of MMC can reduce non-invasive papillary (pTa) bladder cancer recurrences by up to 40%; this treatment is recommended in both the AUA and EUA non-muscle-invasive bladder cancer guidelines. A common complication of this treatment is eosinophilic cystitis. Symptoms range from mild urinary frequency and urgency to debilitating pain and dysuria. Currently, there is no established treatment algorithm for MMC-induced cystitis. Methods: Members of the Urologic Surgery Quality Collaborative (USQC), a group composed of over 160 private and academic urologists, met to discuss the management of patients with cystitis following MMC therapy...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516157/survival-after-metastasectomy-for-metastatic-urothelial-carcinoma-a-systematic-review-and-meta-analysis
#4
Vaibhav Patel, Ana Collazo Lorduy, Aaron Stern, Omar Fahmy, Rachel Pinotti, Matthew D Galsky, Georgios Gakis
Background: Cisplatin-based combination chemotherapy is standard treatment for metastatic urothelial carcinoma; however, the vast majority of patients experience disease progression. As systemic therapy alone is rarely curative for the treatment of metastatic urothelial cancer, not only are new therapies needed but also refinement of general treatment principles. Herein, we conducted a systematic review and meta-analysis to explore the role of metastasectomy in metastatic urothelial carcinoma. Methods: We conducted a systematic review of the literature regarding local treatment for metastatic urothelial carcinoma...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516156/single-arm-phase-i-ii-study-of-everolimus-and-intravesical-gemcitabine-in-patients-with-primary-or-secondary-carcinoma-in-situ-of-the-bladder-who-failed-bacillus-calmette-guerin-nct01259063
#5
Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, Bernard H Bochner, S Machele Donat, Harry W Herr, Asia S Mc Coy, Alicia J Fahrner, Caitlyn Retinger, Jonathan E Rosenberg, Dean F Bajorin
Background: Standard treatment for BCG-refractory urothelial cancer is radical cystectomy. Identification of active agents is clearly warranted. Objective: To determine a safe dose of oral everolimus in combination with standard intravesical gemcitabine and to evaluate the efficacy of this combination. Methods: Patients with carcinoma in situ refractory to intravesical bacillus Calmette-Guérin and refusing cystectomy were eligible. Patients in the phase I part of the trial received one of three dose levels of oral everolimus...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516155/phase-i-clinical-trial-of-everolimus-combined-with-trimodality-therapy-in-patients-with-muscle-invasive-bladder-cancer
#6
Bassel G Bachir, Luis Souhami, Jose João Mansure, Fabio Cury, Marie Vanhuyse, Fadi Brimo, Armen G Aprikian, Simon Tanguay, Jeremy Sturgeon, Wassim Kassouf
Background: Local control following trimodality therapy (TMT) for muscle-invasive bladder cancer (MIBC) requires further optimization. Objective: Evaluating the biologic endpoint, feasibility, and toxicity of integrating everolimus to TMT in patients with MIBC. Methods: This was a phase I trial in patients with MIBC who were not surgical candidates or who refused cystectomy. Following maximal transurethral tumor resection, patients were treated by radiotherapy (50 Gy/20 fractions), gemcitabine (100 mg/m2/weekly) and escalating doses of everolimus (2...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516154/wbc-associates-with-readmission-following-cystectomy
#7
Andrew G McIntosh, Tianyu Li, Timothy Ito, Jason Mannion, Mark Dziemianowicz, Nikhil Waingankar, Mohammed Haseebuddin, David Y T Chen, Richard E Greenberg, Rosalia Viterbo, Alexander Kutikov, Robert G Uzzo, Marc C Smaldone, Philip H Abbosh
Background: Radical cystectomy is associated with perioperative complication rates exceeding 50% in some series. Readmission rates are increasingly used as a surgical quality metric. White blood cell count is a crude surrogate for physiologic processes which may reflect postoperative complications leading to readmission. Objective: We assessed the association between final white blood cell count at discharge and risk of readmission following radical cystectomy. Methods: Records on 477 patients undergoing radical cystectomy from 2006-2013 were reviewed...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516153/neutrophil-to-lymphocyte-ratio-nlr-at-the-time-of-transurethral-resection-of-bladder-tumor-a-large-retrospective-study-and-analysis-of-racial-differences
#8
Ngii N Tazeh, Daniel J Canter, Shivashankar Damodaran, Timothy Rushmer, Kyle A Richards, E Jason Abel, David F Jarrard, Tracy M Downs
Introduction: Neutrophil/lymphocyte ratio (NLR) is an indicator of systemic inflammation and has been proven to be associated with an increased risk of extravesical disease, decreased cancer specific survival and overall survival in bladder cancer patients. A large proportion of healthy African Americans have a WBC count that is persistently lower than the normal range defined for individuals of European ancestry, this condition has been called "benign ethnic neutropenia". The purpose of our study was to determine if NLR was different in patients of African ancestry (AA) vs European ancestry (EA) across different tumor grades and stages at the time of transurethral resection of bladder tumor(s) (TURBT)...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516152/cdk4-6-inhibitors-in-cancer-therapy-a%C3%A2-novel-treatement-strategy-for-bladder-cancer
#9
REVIEW
Qi Pan, Anuja Sathe, Peter C Black, Peter J Goebell, Ashish M Kamat, Bernd Schmitz-Draeger, Roman Nawroth
Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine and, at least in the US, none of the tested agents had been approved for second-line treatment. This has changed with the advent of immune checkpoint blockade, including especially PD-1/PD-L1 inhibitors. The high response rates of 24% over a 14...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149939/a-more-thorough-transurethral-resection
#10
Edward M Messing
No abstract text is available yet for this article.
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149938/challenging-cases-in-urothelial-cancer
#11
Mark S Soloway
No abstract text is available yet for this article.
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149937/efficacy-of-mycobacterium-phlei-cell-wall-nucleic-acid-complex-mcna-in%C3%A2-bcg-unresponsive-patients
#12
Roger Li, John Amrhein, Zvi Cohen, Monique Champagne, Ashish M Kamat
Background: We have previously reported the results of a prospective multi-institutional study on the efficacy of MCNA in patients who recurred after intravesical BCG treatment [1]. Since that publication, a new standardized definition for BCG-unresponsiveness has been established [2]. Objective: We re-analyzed the oncologic outcomes following intravesical MCNA in patients classified as BCG-unresponsive according to the new definition. Methods: For this analysis, we focused on the enrolled patients who satisfied the requirements for BCG Unresponsiveness: i...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149936/change-in-psoas-muscle-volume-as-a-predictor-of-outcomes-in-patients-treated-with-chemotherapy-and-radical-cystectomy-for-muscle-invasive-bladder-cancer
#13
Homayoun Zargar, Nima Almassi, Evan Kovac, Cesar Ercole, Erick Remer, Brian Rini, Andrew Stephenson, Jorge A Garcia, Petros Grivas
Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of perioperative complications, pathologic response or survival. Methods: During the period of 2009-2013, patients undergoing NAC and radical cystectomy (RC) at our institution with pre and post NAC cross sectional images available were included...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149935/readmission-rate-and-causes-at-90-day-after-radical-cystectomy-in-patients-on-early-recovery-after-surgery-protocol
#14
Emanuela Altobelli, Maurizio Buscarini, Harcharan S Gill, Eila C Skinner
Background: Radical cystectomy (RC) is associated with high risk of early and late perioperative complications, and readmissions. The Enhanced Recovery After Surgery (ERAS) protocol has been applied to RC showing decreased hospital stay without increased morbidity. Objective: To evaluate the specific causes of hospital readmissions in RC patients treated before and after adoption of an ERAS protocol at our institution. Methods: We retrospectively evaluated the outcome of 207 RC patients on ERAS protocol at the Stanford University Hospital from January 2012 to December 2014...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149934/dipstick-urinalysis-as-a-test-for-microhematuria-and-occult-bladder-cancer
#15
Richard S Matulewicz, John Oliver DeLancey, Emily Pavey, Edward M Schaeffer, Oana Popescu, Joshua J Meeks
Introduction: There is a lack of evidence supporting the routine use of laboratory tests to detect bladder cancer. Identifying a cost-effective and widely available diagnostic aid may improve bladder cancer outcomes. We sought to evaluate the utility of dipstick urinalysis to detect microhematuria and diagnose bladder cancer in a large, diverse, contemporary cohort. Methods: All non-pregnant women and men 35 and older with a new diagnosis of microhematuria (≥3 RBC/hpf) were identified via a multi-center electronic medical record data warehouse query...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149933/utility-of-clinical-risk-stratification-in-the-selection-of-muscle-invasive-bladder-cancer-patients-for-neoadjuvant-chemotherapy-a-retrospective-cohort-study
#16
Friedrich-Carl von Rundstedt, Douglas A Mata, Oleksandr N Kryvenko, Anup A Shah, Iny Jhun, Seth P Lerner
Introduction: Level I evidence supports the use of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer prior to radical cystectomy (RC). On average, 30-40% of patients achieve a complete pathologic response (i.e., stage pT0) after receiving NAC. Some centers risk-stratify patients, suggesting that there may be a higher-risk population that would derive the most benefit from NAC. Recently, a risk-stratification model developed at M.D. Anderson Cancer Center (MDACC) specified criteria for clinical staging and patient selection for NAC...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149932/aquaporin-3-expression-loss-in-urothelial-carcinoma-association-with-tumor-invasion-depth-but-not-with-grading
#17
Johannes Breyer, Wolfgang Otto, Maximilian Burger, Arndt Hartmann, Peter C Rubenwolf
We have previously provided molecular evidence of expression of aquaporin 3 (AQP3) in normal human urothelium and in UBC of various stages. Whereas former studies demonstrated that loss of AQP3 was associated with invasive and high-grade disease and worse progression-free and cancer-specific survival, this report investigates the expression of AQP3 in associated CIS. Contrary to what we had expected, all CIS specimens were shown to exhibit strong AQP3 expression, suggesting loss of AQP3 in UBC is primarily associated with the ability of tumor cells for invasion but not with grading as sign of dedifferentiation...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149931/the-rationale-for-post-operative-radiation-in-localized-bladder-cancer
#18
REVIEW
Brian C Baumann, Paul Sargos, Libni J Eapen, Jason A Efstathiou, Ananya Choudhury, Amit Bahl, Vedang Murthy, Leslie K Ballas, Valérie Fonteyne, Pierre M Richaud, Mohamed S Zaghloul, John P Christodouleas
Local-regional recurrence for patients with ≥pT3 disease after radical cystectomy is a significant problem. Chemotherapy has not been shown to reduce the risk of local-regional recurrences in randomized prospective trials, and salvage therapies for local-regional failure are rarely successful. There is promising evidence, particularly from a recent Egyptian NCI trial, that radiation therapy plus chemotherapy can significantly reduce local recurrences compared to chemotherapy alone, and that this improvement in local-regional control may translate to meaningful improvements in disease-free and overall survival with acceptable toxicity...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149930/ten-years-of-proteomics-in-bladder-cancer-progress-and-future-directions
#19
REVIEW
Maria Frantzi, Antonia Vlahou
Research efforts targeting the identification of bladder cancer biomarkers have been extensive during the past decade. Investigations have been performed at the genome, transcriptome, proteome, and metabolome levels and outputs have started appearing including the sketching of disease molecular subtypes. Proteins are directly linked to cell phenotype hence they accumulate special interest as both biomarkers and therapeutic targets. Multiple technical challenges exist, of the main, being the protein concentration vast dynamic range and presence of proteins in modified forms...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28035330/checkpoint-inhibitors-for-advanced-bladder-cancer
#20
Edward M Messing
No abstract text is available yet for this article.
October 27, 2016: Bladder Cancer
journal
journal
52783
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"